Skip to main
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc. is projected to achieve approximately $32 million in top-line revenue for 2025, with expectations for growth to $130.4 million in 2026, indicating a strong trajectory in revenue generation. The favorable market access situation is anticipated to enhance coverage over the coming months, potentially contributing to an increase in revenue beyond the current forecasts. Additionally, the company's promising pipeline assets, including therapies for rare genetic diseases, are expected to provide incremental upside to the financial outlook as their clinical development progresses.

Bears say

Abeona Therapeutics faces significant risks that contribute to a negative outlook on its stock, notably the potential for slower-than-projected market uptake of its flagship product, pz-cel, in the United States. Additionally, the company's inability to effectively capitalize on pz-cel’s value outside of the U.S. and challenges with earlier-stage pipeline programs further exacerbate concerns about its growth potential. Furthermore, there exists a persistent risk of long-term dilution, which may adversely affect shareholder value and investor confidence.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.